Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03134638 · ClinicalTrials.gov registry record · Phase 1
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Syros Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT03134638 is a Phase 1 study that was terminated before completion, run by Syros Pharmaceuticals. The registered enrollment target is 107 participants.
The verdict
NCT03134638, a Phase 1 study, was terminated before completion, sponsored by Syros Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety and the antitumor activity of SY-1365 in patients with select solid tumors, and to confirm target engagement and downstream pathway impact in patients with any solid tumor histology.
Interventions
- DRUG Carboplatin
- DRUG Fulvestrant
- DRUG SY-1365 (Part 1)
- DRUG SY-1365 (Cohort 2)
- DRUG SY-1365 (Cohort 5)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-05-12 |
| Est. Completion | 2020-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03134638
The ClinicalTrials.gov registry entry for NCT03134638 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syros Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03134638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03134638 about?
NCT03134638 is a clinical study titled "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors". This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2. Following the identification of a recommended dose and regimen from Part 1, the study entered Part 2 to further evaluate safety a...
What is the current status of trial NCT03134638?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2017-05-12. Estimated completion is 2020-06-24.
What interventions are being tested in trial NCT03134638?
The interventions under investigation include: Carboplatin (DRUG), Fulvestrant (DRUG), SY-1365 (Part 1) (DRUG), SY-1365 (Cohort 2) (DRUG), SY-1365 (Cohort 5) (DRUG).
Who is sponsoring clinical trial NCT03134638?
This trial is sponsored by Syros Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.